Division of Developmental and Behavioral Pediatrics (KE Wallis, AE Bennett, JS Miller, and W Guthrie), Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Pediatrics (KE Wallis, AE Bennett, AG Fiks, M Gerdes, BP Jenssen, JS Miller, D Shu, and W Guthrie), Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa; Center for Autism Research (KE Wallis, AE Bennett, JS Miller, and W Guthrie), Children's Hospital of Philadelphia, Philadelphia, Pa; Center for Pediatric Clinical Effectiveness (KE Wallis, E Nekrasova, AG Fiks, M Gerdes, BP Jenssen, D Shu, and W Guthrie), Children's Hospital of Philadelphia, Philadelphia, Pa.
Center for Pediatric Clinical Effectiveness (KE Wallis, E Nekrasova, AG Fiks, M Gerdes, BP Jenssen, D Shu, and W Guthrie), Children's Hospital of Philadelphia, Philadelphia, Pa; The Possibilities Project (E Nekrasova, AG Fiks, BP Jenssen), Children's Hospital of Philadelphia, Philadelphia, Pa.
Acad Pediatr. 2022 Nov-Dec;22(8):1384-1389. doi: 10.1016/j.acap.2022.04.005. Epub 2022 Apr 20.
To assess the impact of the COVID-19 pandemic on screening for autism spectrum disorder (ASD) and screening equity among eligible children presenting for well-child care in a large primary care pediatric network, we compared rates of ASD screening completion and positivity during the pandemic to the year prior, stratified by sociodemographic factors.
Patients who presented for in-person well-child care at 16 to 26 months between March 1, 2020 and February 28, 2021 (COVID-19 cohort, n = 24,549) were compared to those who presented between March 1, 2019 and February 29, 2020 (pre-COVID-19 cohort, n = 26,779). Demographics and rates of completion and positivity of the Modified Checklist for Autism in Toddlers with Follow-up (M-CHAT/F) were calculated from the electronic health record and compared by cohort using logistic regression models.
Total eligible visits decreased by 8.3% between cohorts, with a greater decline in Black and publicly insured children. In the pre-COVID-19 cohort, 89.0% of eligible children were screened at least once, compared to 86.4% during the pandemic (P < 0.001). Significant declines in screening completion were observed across all sociodemographic groups except among Asian children, with the sharpest declines among non-Hispanic White children. Sociodemographic differences were not observed in screen-positive rates by cohort.
Well-child visits and ASD screenings declined across groups, but with different patterns by race and ethnicity during the COVID-19 pandemic. Findings regarding screen-completion rates should not be interpreted as a decline in screening disparities, given differences in who presented for care. Strategies for catch-up screening for all children should be considered.
评估 COVID-19 大流行对在大型初级保健儿科网络中符合条件的儿童进行自闭症谱系障碍(ASD)筛查以及筛查公平性的影响,我们比较了大流行期间和前一年进行 ASD 筛查完成率和阳性率,按社会人口因素分层。
2020 年 3 月 1 日至 2021 年 2 月 28 日期间,16 至 26 个月龄因常规健康儿童就诊而在门诊就诊的患者(COVID-19 队列,n=24549)与 2019 年 3 月 1 日至 2020 年 2 月 29 日期间就诊的患者(COVID-19 前队列,n=26779)进行比较。从电子健康记录中计算出改良婴幼儿自闭症检查表随访版(M-CHAT/F)的完成率和阳性率,并使用逻辑回归模型按队列进行比较。
两个队列之间的合格就诊次数减少了 8.3%,黑人和有公共保险的儿童就诊次数下降幅度更大。在 COVID-19 前的队列中,89.0%的合格儿童至少接受了一次筛查,而在大流行期间为 86.4%(P<0.001)。除了亚洲儿童外,所有社会人口统计学群体的筛查完成率均显著下降,其中非西班牙裔白人儿童的下降幅度最大。两个队列之间在筛查阳性率方面没有观察到社会人口统计学差异。
在 COVID-19 大流行期间,所有群体的常规儿童就诊和 ASD 筛查均有所下降,但按种族和族裔的模式不同。鉴于就诊者的不同,不能将筛查完成率的下降解释为筛查差异的减少。应考虑为所有儿童制定追赶筛查策略。